Possibia

3876938

Last Update Posted: 2019-03-15

Recruiting status is unknown

All Genders

accepted

18 Years +

147 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy

Aprepitant and olanzapine have been recommended for emesis prevention from highly emetogenic chemotherapy. We hypothesized that olanzapine may lead to less nausea compared to aprepitant based on previous study. However, data of combination of olanzapine and ondansetron is scarce.

Aprepitant and olanzapine have been recommended for emesis prevention from highly emetogenic chemotherapy. We hypothesized that olanzapine may lead to less nausea compared to aprepitant based on previous study. However, data on efficacy and adverse effects of combination of olanzapine and ondansetron which is only serotonin antagonist in Thai national essential drug list, is scarce. Also, we aims to assess the efficacy of olanzapine dosage of 5 mg which is more commonly used in Thai patients.

Eligibility

Relevant conditions:

Antiemetic for Highly Emetogenic Chemotherapy

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

Suthinee Ithimakin, MD

aesi105@yahoo.co.th

+6624194489

Data sourced from ClinicalTrials.gov